 Oncocyte Corporation NYSE American: OCX, a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced the completion of the Clinical Validation study of DetermaDxTM, the Companys liquid biopsy test intended to clarify whether a lung nodule is suspicious or likely benign. Findings from the Clinical Validation study demonstrated that the performance of DetermaDx did not meet the predetermined endpoints for the study. 